Private Equity: Key Risks, Deadlines, and Next Steps

When a fund makes a capital call, limited partners typically have a fixed window (often 10 to 15 business days) to fund their commitment. Failure to meet the deadline triggers automatic penalties, which may include loss of the investment opportunity, dilution of the LP's interest, or forced assignment of the commitment to other LPs. The practical consequence is that an LP who misses a call deadline may lose not only the specific investment but also a portion of overall fund economics.

Management fees are typically calculated as a percentage of committed capital or net asset value. The agreement usually specifies whether certain expenses (legal, audit, placement fees) are borne by the fund or charged to LPs separately. In practice, these calculations are often contested during fund wind-down or when performance falters. Clawback provisions obligate the general partner to return previously distributed carried interest if the fund underperforms relative to the preferred return hurdle. Courts in New York have upheld clawback obligations as binding contractual commitments, even when they result in substantial GP liability.

Private equity sponsors typically secure board control through preferred stock provisions or contractual board designation rights. Board members appointed by the sponsor owe fiduciary duties to the company and all shareholders, not solely to the sponsor. This creates tension when sponsor interests (e.g., cost-cutting for near-term cash flow) diverge from long-term company value. Courts increasingly scrutinize sponsor-directed decisions that benefit the PE firm at the expense of minority holders or creditors. In a Delaware Chancery Court decision, a court found that a sponsor's use of a portfolio company's cash for dividend recapitalizations, undertaken without full disclosure to minority shareholders, constituted a breach of fiduciary duty.

Minority shareholders often have limited contractual protections in PE-backed companies. Drag-along provisions allow the majority to force minorities into a sale at the same price per share, without independent negotiation rights. Tag-along rights give minorities the right to participate in a sale on the same terms. The interplay between these provisions, redemption rights, and information access creates recurring disputes. In New York courts, minority shareholders have challenged drag-along exercises when they believed the sale price was artificially depressed or when the sponsor had a conflicting interest in the buyer.

Fund agreements often require independent appraisals for illiquid holdings at year-end. Disagreement over valuation methodology (comparable company multiples, discounted cash flow analysis, or recent transaction data) is routine. The agreement should specify which methodology governs and whether the GP has discretion to override an appraiser's conclusion. When disputes arise, litigation can take years and consume substantial legal fees. Securing an independent valuation upfront, with clear methodology agreed in advance, reduces exposure significantly.

When a fund sells a portfolio company to a secondary buyer (another PE firm or strategic buyer), the sponsor often faces a conflict: a higher sale price benefits LPs, but it reduces the sponsor's ability to realize a higher multiple on a future sale. Courts have held that sponsors cannot use information asymmetry or control of the sales process to favor their own interests. In practice, this means the sponsor should disclose competing offers, engage an independent financial advisor, and document the fairness of the process.

Most private equity funds rely on the Regulation D exemption from Securities Act registration, which requires that the fund not solicit or advertise publicly and that it maintain detailed records of investor accreditation. If a fund violates these conditions, the SEC can bring enforcement action, and investors may have rescission rights. Compliance requires careful documentation of the offering process and investor qualification. The SEC has brought actions against sponsors who used general advertising or accepted non-accredited investors, resulting in substantial penalties and forced fund wind-downs.

Most private equity fund agreements include New York choice-of-law and forum-selection clauses. When disputes arise, they are often litigated in New York Supreme Court (Commercial Division) or federal court (Southern District of New York). New York courts have developed substantial case law on LP rights, GP duties, and the enforceability of fund document provisions. Familiarity with New York precedent on carried interest allocation, clawback procedures, and minority shareholder oppression is critical to evaluating settlement value and litigation strategy in fund disputes.

The strategic priority is to address governance and valuation issues before they crystallize into disputes. Early documentation of the fund structure, clear allocation of decision-making authority, and transparent valuation processes reduce litigation exposure significantly. Investors and sponsors should also maintain robust compliance with securities law requirements and tax filings to avoid regulatory surprises during fund wind-down or exit. For healthcare private equity transactions, additional regulatory requirements apply, including healthcare regulatory compliance and fraud and abuse law considerations. Sponsors engaged in private equity financing should also evaluate whether the fund structure and LP agreement accommodate future refinancing or secondary market sales without triggering unintended tax consequences or control issues.